Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited has consolidated its shareholding in biopharma subsidiary Gennova Biopharmaceuticals Limited, acquiring the entire 12.05% minority stake held by Dr. Sanjay Singh and others, making Gennova a wholly owned subsidiary. Gennova will be led by Mr. Samit Mehta and will focus on its biologics franchise, biosimilars development, and adjacent therapeutic platforms.

Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited has acquired 12.05% stake in its subsidiary Gennova Biopharmaceuticals Limited for Rs. 2,318.7 million.

Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited has submitted a revised intimation of Confirmation under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended June 30, 2026, with a correct enclosure.

Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018. The company has received a Confirmation Certificate from MUFG Intime India Private Limited, the Registrar and Share Transfer Agent (RTA) of the Company, for the quarter ended June 30, 2026.

Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited has informed the Exchange about the acquisition of Mantra Pharma Inc., a step-down subsidiary of the Company, by Marcan Pharmaceuticals Inc., another subsidiary of the Company, for an aggregate consideration of CAD $50 million.

Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited has informed the Exchange about change in Management, with Mr. Kuber Jagdale, President – API Business, superannuating from his employment with the Company with effect from close of business hours on June 30, 2026.

Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited has informed the Exchange regarding the closure of the trading window for its designated persons and their immediate relatives due to the declaration of unaudited financial results for the quarter ending June 30, 2026.

Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited disclosed under SEBI Takeover Regulations that except for Smita Paresh Shah's pledge of 60,000 equity shares, there are no encumbrances on the equity shares held by promoters during the FY ended March 31, 2026.

Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited announced the allotment of 20,600 equity shares on June 19, 2026. These shares, each with a face value of Rs. 10, were issued pursuant to the exercise of Employee Stock Options (ESOPs) under the company's 2013 scheme. The Nomination and Remuneration Committee approved this allotment. This action serves to incentivize employees, leading to a minor dilution in the existing shareholding base.